KA
NVS icon

Kozak & Associates’s Novartis NVS Stock Holding History

Kozak & Associates’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.24K Hold
21
– – ﹤0.01% 339
2026
Q1 		$3.24K Hold
21
– – ﹤0.01% 345
2025
Q4 		$2.97K Hold
21
– – ﹤0.01% 351
2025
Q3 		$2.76K Sell
21
-979
-98% -$119K ﹤0.01% 363
2025
Q2 		$123K Buy
+1,000
New +$113K 0.03% 100

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Kozak & Associates's NVS Position: Q2 2026 in Review

Kozak & Associates held its Novartis (NVS) position steady in Q2 2026 at 21 shares worth $3.24K. The position accounts for ﹤0.01% of the portfolio, ranked #339.

Kozak & Associates first reported a position in NVS in Q2 2025 and has held it in 5 quarters since. The position peaked at $123K in Q2 2025. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Kozak & Associates held 21 shares of Novartis worth $3.24K as of Q2 2026.
  • Kozak & Associates left its Novartis share count unchanged in Q2 2026.
  • Novartis made up ﹤0.01% of Kozak & Associates's portfolio in Q2 2026, its #339 holding.
  • Kozak & Associates first reported a position in Novartis in Q2 2025 and has held it in 5 quarters since.
  • Kozak & Associates's Novartis position peaked at $123K in Q2 2025.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.